Lucid Diagnostics Reports 95% Success Rate in 11,991 EsoGuard Tests for Esophageal Cancer Screening
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- Technical Success Rate: Lucid's EsoGuard® test achieved a 95% technical success rate across 11,991 patients, demonstrating its effectiveness in esophageal cancer screening and reinforcing the company's market position in cancer prevention.
- Rapid Sampling Time: The EsoCheck® device's cell collection time averages under two minutes, which not only enhances clinical efficiency but also enables physicians to quickly identify patients needing further endoscopy, thereby reducing unnecessary invasive procedures.
- Wide Clinical Application: The study indicates that EsoCheck can be safely and efficiently performed in diverse clinical settings, showcasing its scalability and enhancing Lucid's competitive edge in the market.
- Optimistic Market Outlook: With the growing demand for early esophageal cancer screening, Lucid's technology is seen as pivotal for widespread adoption, expected to drive further growth in the cancer prevention market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LUCD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LUCD
Wall Street analysts forecast LUCD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LUCD is 4.05 USD with a low forecast of 3.00 USD and a high forecast of 8.25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.140
Low
3.00
Averages
4.05
High
8.25
Current: 1.140
Low
3.00
Averages
4.05
High
8.25
About LUCD
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans
- Contract Approval: Lucid Diagnostics has secured a contract with the Department of Veterans Affairs for its EsoGuard test, significantly enhancing access across the nationwide healthcare system serving over 9 million veterans, thereby strengthening the company's competitive position in the healthcare market.
- Standardized Procurement: The contract allows VA hospitals to procure EsoGuard through a unified framework, ensuring pre-negotiated pricing aligned with Medicare payment standards, which simplifies the procurement process and reduces operational costs.
- Clinical Evidence Support: Lucid stated that the award reflects the clinical evidence supporting the EsoGuard test, further solidifying its potential for integration into standard clinical practice and possibly facilitating collaborations with other integrated health systems.
- Market Performance Analysis: PAVmed shares are currently trading at $11.46, 40.4% above the 20-day simple moving average but 0.8% below the 100-day average, indicating strong short-term performance but potential long-term weakness in market signals.
Continue Reading
Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%
- Contract Approval: Lucid Diagnostics has secured a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing for over nine million veterans, which is expected to significantly enhance the company's influence in the healthcare market.
- Pricing Advantage: The contract includes pre-negotiated pricing aligned with Medicare payment rates, allowing VA facilities to procure EsoGuard through a streamlined process, further strengthening the product's market competitiveness.
- Stock Performance: PAVmed's stock surged by 291.11% to $17.80 on Wednesday, reflecting strong short-term market performance and aligning with the positive trends in the Nasdaq and S&P 500 indices.
- Technical Indicators: PAVmed is currently trading 167.1% above its 20-day simple moving average, indicating strong short-term technical indicators; although the relative strength index (RSI) is in neutral territory, the MACD shows bullish momentum, suggesting optimistic market sentiment.
Continue Reading